Metabolic Panel Testing Market Size & Share, by Disease (Kidney Diseases, Diabetes, Liver Diseases); Test Type (Electrolytes, Proteins, Kidney Tests, Glucose, Liver Functional Tests); End-user (Point-of-Care Centers, Laboratories) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2031

  • Report ID: 3994
  • Published Date: Feb 02, 2023
  • Report Format: PDF, PPT

Global Metabolic Panel Testing Market Highlights Over 2022 - 2031

The global metabolic panel testing market is estimated to garner a sizeable revenue by growing at a CAGR of ~7% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increasing awareness among people regarding early diagnosis and treatment of diseases, and growing prevalence of chronic diseases around the world. Along with these, rising number of incidences lifestyle-associated diseases, including obesity, coupled with the escalating adoption of unhealthy habits such as smoking, excessive drinking and lack of physical activities are also expected to drive significant market growth in the forthcoming years. According to the World Health Organization (WHO), about 38.2 million children under the age of 5 years were overweight or obese in the year 2019. Worldwide obesity has grown by more than 3 times since 1975. Furthermore, developments in point-of-care technologies and diagnostics globally are projected to offer lucrative opportunities for market growth in the near future.

Metabolic Panel Testing Market

The market is segmented by disease into kidney diseases, diabetes, liver diseases, and others, out of which, the kidney diseases segment is anticipated to hold the largest share in the global metabolic panel testing market. This can be accounted to the growing occurrence of kidney diseases, and rapid shift in the lifestyle of people worldwide. Apart from this, the diabetes segment is predicted to observe significant growth over the forecast period owing to the increasing cases of diabetes and cardiovascular diseases, and rising demand for immediate diagnosis of these diseases. Additionally, on the basis of end user, the laboratories segment is assessed to grab the largest share over the forecast period ascribing to the high preference of patients to get test results from reputed laboratories, and their affiliation with blood banks, hospitals and specialty diagnostic centers. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita, (USD), 2015-2018

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Metabolic Panel Testing Market Regional Synopsis

Regionally, the global metabolic panel testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the improvements in healthcare infrastructure, and rising disposable income in the region. Moreover, the market in North America is expected to grab the largest share during the forecast period owing to the high healthcare spending, and strong commercial presence of metabolic panel diagnostics in the region. As per the Centers for Medicare & Medicaid Services (CMS), the healthcare spending in the United States grew by 9.7 percent in 2020, amounting for a value of USD 1.4 trillion. As a share of the nation's GDP, health spending accounted for 19.7 percent. In addition, favorable reimbursement policies provided by the government is also projected to drive market growth in the region in the coming years. 

Metabolic Panel Testing Market Share

The global metabolic panel testing market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global metabolic panel testing market includes the following segments:

By Disease

  • Kidney Diseases
  • Diabetes
  • Liver Diseases
  • Others

By Test Type

  • Electrolytes
  • Proteins
  • Kidney Tests
  • Glucose
  • Liver Functional Tests
  • Others

By End User

  • Point-of-Care Centers
  • Laboratories

Growth Drivers

  • Increasing Awareness Among People Regarding Early Diagnosis and Treatment of Diseases
  • Growing Prevalence of Chronic Diseases Around the World

Challenges

  • High Cost of Metabolic Panel Testing

Top Featured Companies Dominating the Market

  • SYNLAB International GmbH
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Abbott Laboratories
  • Quest Diagnostics, Inc.
  • Laboratory Corporation of America Holdings
  • Sonic Healthcare Limited
  • Associated Regional and University Pathologists, Inc.
  • Nova Biomedical
  • WerfenLife, S.A.
  • Scion Lab Services, LLC


In-the-news

In the News

  • April 2020- Nova Biomedical declared that the U.S. Food and Drug Administration (FDA) approved its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care use. The technology provides 19 essential critical care tests, including blood gases, electrolytes, metabolites, hematology, and co-oximetry.

  • June 2021- Abbott launched rapid point-of-care HBA1C test to help professionals in the diagnosis of diabetes and the assessment of patient’s risk to develop the condition.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3994
  • Published Date: Feb 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving market growth owing to the increasing awareness among people regarding early diagnosis and treatment of diseases, and growing prevalence of chronic diseases around the world.

The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2022-2031.

The major players in the market are SYNLAB International GmbH, Abbott Laboratories, Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease, test type, end user, and by region.

The kidney diseases segment is anticipated to hold largest market size and is estimated grow at a steady CAGR over the forecast period and display significant growth opportunities.

High cost of metabolic panel testing is estimated to hamper the market growth.

Asia Pacific will provide more business opportunities for market growth owing to the improvements in healthcare infrastructure, and rising disposable income in the region.
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying